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Introduction: Community acquired pneumonia (CAP) is the most common infectious reason for admission to the
Intensive Care Unit (ICU). The GenOSept study was designed to determine genetic influences on sepsis outcome.
Phenotypic data was recorded using a robust clinical database allowing a contemporary analysis of the clinical
characteristics, microbiology, outcomes and independent risk factors in patients with severe CAP admitted to ICUs
across Europe.
Methods: Kaplan-Meier analysis was used to determine mortality rates. A Cox Proportional Hazards (PH) model was
used to identify variables independently associated with 28-day and six-month mortality.
Results: Data from 1166 patients admitted to 102 centres across 17 countries was extracted. Median age was 64 years,
62% were male. Mortality rate at 28 days was 17%, rising to 27% at six months. Streptococcus pneumoniae was the
commonest organism isolated (28% of cases) with no organism identified in 36%. Independent risk factors associated
with an increased risk of death at six months included APACHE II score (hazard ratio, HR, 1.03; confidence interval, CI,
1.01-1.05), bilateral pulmonary infiltrates (HR1.44; CI 1.11-1.87) and ventilator support (HR 3.04; CI 1.64-5.62). Haematocrit,
pH and urine volume on day one were all associated with a worse outcome.
Conclusions: The mortality rate in patients with severe CAP admitted to European ICUs was 27% at six months.
Streptococcus pneumoniae was the commonest organism isolated. In many cases the infecting organism was not
identified. Ventilator support, the presence of diffuse pulmonary infiltrates, lower haematocrit, urine volume and pH
on admission were independent predictors of a worse outcome.Introduction
Community acquired pneumonia (CAP) is common,
affecting between 5 and 11 individuals per 1,000 of the
adult population each year [1,2] and is the commonest
cause of sepsis, severe sepsis and septic shock [3]. Between
22 and 42% of patients require hospital admission [1,2,4]
of whom 5 to 10% will be admitted to an ICU [5-7].
Hospital and ICU admission rates for CAP are increasing
for all ages [8]. An ageing, more vulnerable population,
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reproduction in any medium, provided the oravailability and use of intensive care beds may in part
explain this increase.
A number of investigators have examined the clinical
and microbiological factors that might affect the outcome
from severe CAP [5-7,9-23], but these studies have often
been relatively small, with considerable heterogeneity in
both the inclusion criteria and outcome measures. As a
consequence reported mortality rates have varied and
there has been uncertainty regarding the most important
risk factors for death. A number of more recent, larger
studies have focussed on identifying patients with CAP
at increased risk of severe sepsis and death, as well as
those who may require ventilator or vasopressor support
[3,24-26]. One of these studies provides outcome data atl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sepsis admitted to the ICU [3], and another [24] reports
microbiological findings and 90-day mortality in a sub-
group of 170 patients admitted to the ICU.
The aim of the study reported here was to define the
clinical characteristics, microbiological aetiology, outcomes
and independent risk factors for mortality in a large,
contemporary cohort of patients with severe CAP admit-
ted to ICUs across Europe. By using such a large database
with clear censor data for mortality we hoped to overcome
some of the deficiencies of previous studies.
Materials and methods
The GenOSept study was conceived by the European
Critical Care Research Network (ECCRN), the research
arm of the European Society for Intensive Care Medicine
(ESICM) with the aim of defining genetic influences on
the host response and outcomes in patients with sepsis.
GenOSept is a pan-European study that has recorded
comprehensive phenotypic data and obtained DNA from
a large cohort of patients admitted to ICU with sepsis due
to CAP, peritonitis, meningococcal disease or pancreatitis.
Ethics approval was granted nationally, for individual
centres, or for both. Written, informed consent was
obtained from all patients or a legal representative.
Patients reported here were recruited into GenOSept
from 102 centres across 17 countries (see Additional
file 1 for contributors) over a 4-year period between
September 2005 and October 2009.
Inclusion criteria were as follows: admission to a high
dependency unit (HDU) or ICU with CAP, and age over
18 years. The diagnosis of CAP was defined as a febrile
illness associated with cough, sputum production, breath-
lessness, leucocytosis and radiological features of pneumo-
nia acquired in the community or within less than 2 days of
hospital admission [24]. The diagnosis of sepsis was based
upon the International Consensus Criteria published in
2003 [27]. Patients were further sub-classified according
to the criteria for severe sepsis and septic shock.
Exclusion criteria were as follows: patient or legal repre-
sentative unwilling or unable to give consent; patient under
18 yrs of age; patient pregnant; advanced directive to with-
hold or withdraw life-sustaining treatment or admitted for
palliative care only (please see also Additional file 1).
Patients were observed until death or for a maximum
of 6 months. In those who had died between ICU discharge
and 6-month follow-up the date of death was recorded.
Specific data was recorded in the electronic case report
form (eCRF) to allow calculation of the acute physiology
and chronic health evaluation II (APACHE II) and sequen-
tial organ failure assessment (SOFA) scores [28,29]. The
Infectious Diseases Society of America/American Thoracic
Society (IDSA/ATS) criteria were used for the diagnosis of
severe CAP [30]. Co-morbidities were recorded accordingto the modified Charlson scoring system [31]. Chest radio-
graph appearances were recorded as: 1) lobar, 2) localised
or 3) diffuse bilateral. Investigators were also asked to
consider the differential diagnosis of cardiogenic pulmon-
ary oedema in those with diffuse pulmonary infiltrates.
Microbiological investigations were performed according
to local policies and practices. Investigators recorded
the microbiological findings, including the organism(s) iso-
lated, the source of the organism and the use of serology.
Statistical methods
Mortality at 28 days and at 6 months were chosen as
primary endpoints. Univariate analysis was performed
using a Cox proportional hazards model, adjusted for
age and gender. Variables considered by the investigators
to be clinically relevant were chosen for analysis (see
Additional file 1). A test for proportional hazards using the
Schoenfeld residuals was performed, and for covariates
indicating evidence of non-proportionality, spline smooth
estimates of time-dependent hazard ratios (HRs) with
point-wise confidence bands were calculated [32]. Vari-
ables that were significant in the univariate analysis after
Bonferroni adjustment for multiple testing (P-value <0.05/k
where k is the number of variables tested) were entered
into a multivariate Cox proportional hazards model to
determine independent risk factors for death. A final set of
predictors for each of 28-day and 6-month mortality was
selected from these variables via a stepwise Cox propor-
tional hazards regression model. R software version 2.11.1
was used for all data analysis.
Results
Between 29 September 2005 and 13 October 2009, 1,170
patients were enrolled. Four individuals were excluded
because of missing or inconsistent data. Patient character-
istics are shown in Table 1. On admission, 1,135 patients
(97%) met IDSA/ATS criteria for severe CAP, 991 on
major criteria and 146 on minor criteria.
Median age was 64 years (range 18 to 101, IQR 51 to
71): 62% were male, 81% were Caucasian and 13%
Mediterranean, and 509 patients were hospitalised for
more than 24 hours prior to ICU admission. Of these the
mean time from hospital admission to ICU admission was
1.04 days. Median length of stay in the ICU was 11 days
(IQR 6 to 23); median length of stay in hospital was
22 days (IQR 13 to 40) (Table 1).
A total of 718 (62%) patients had one or more co-morbid
conditions, with cardiac and respiratory disease affecting
458 and 531 patients, respectively. Chronic obstructive pul-
monary disease was documented in 278 (23.8%) patients,
diabetes mellitus in 19.6% and a chronic neurological
condition in 13.1%.
On the day of admission 884 (76%) patients required
mechanical ventilation, with the number increasing to
Table 1 Demographic data for patients with CAP
admitted to adult ICUs across Europe
Case mix Number analysed Number (%)
Age 1,166
<24 years 23 2
24 to <34 years 54 4.6
34 to <44 years 118 10.1
44 to <54 years 146 12.5
54 to <64 years 237 20.3
64 to <74 years 286 24.5
74 to <84 years 247 21.2
≥84 years 55 4.7
Gender 1,166
Male 722 61.9
Female 444 38.1
Race 1,152
African 17 1.5
Asian 11 1
Caucasian 940 81.6
Hispanic 34 3
Indian 3 0.3
Mediterranean 147 12.8
Country 1,166
Belgium 147 12.6
Czech Republic 40 3.4
Germany 35 3
Estonia 17 1.5
Spain 194 16.6
France 97 8.3
Greece 6 0.5
Croatia 4 0.3
Ireland 21 1.8
Israel 5 0.4
Italy 51 4.4
Netherlands 2 0.2
Poland 50 4.3
Serbia 2 0.2
United Kingdom 495 42.5
Medical co-morbidities
Heart and vascular disease 1,164 458 39.3
Respiratory disease 1,163 531 45.7
Neurological disease 1,164 153 13.1
Severe renal disease 1,134 79 7
Gastrointestinal disease 1,164 139 11.9
Malignancy 1,164 108 9.3
Table 1 Demographic data for patients with CAP
admitted to adult ICUs across Europe (Continued)
Diabetes 1,164 228 19.6
Other illness 1,164 145 12.5
Days in ICU 1,166
<3 103 8.8
3 to <7 286 24.5
7 to <14 311 26.7
14 to <28 257 22
28 to <56 160 13.7
56 to 250 49 4.2
Days in hospital from ICU admission 1,166
<7 63 5.4
7 to <14 200 17.2
14 to <28 310 26.6
28 to <56 224 19.2
56 to <250 126 10.8
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(Table 2). Median duration of mechanical ventilation was
7 days: 573 patients (49%) satisfied the criteria for septic
shock. The median duration of inotrope/vasopressor sup-
port was 3 days. Renal replacement therapy was required
during the first week of admission in 10% of patients.
Median SOFA score on admission was 6 (IQR 4 to 9)
and median APACHE II score was 20 (IQR 15 to 25).
Chest radiograph appearances were recorded as lobar
consolidation in 43.7%, patchy localised consolidation in
25.0% and diffuse, bilateral changes in 29.3%.
A total of 316 (27.3%) patients had died within 6 months
of enrolment, 222 (19.0%) in the ICU, 63 in hospital after
ICU discharge and 31 between hospital discharge and
6 months following ICU admission. The in-hospital mor-
tality rate was 24.4% and the 28-day mortality rate was
17.3% (see Table 3 and Figure 1). Mortality was higher in
mechanically ventilated patients, (24.9% at 28 days and
33.6% at 6 months) and in patients with septic shock
receiving haemodynamic support with inotropes or vaso-
pressors (28.8% and 38.6% respectively). The standardised
mortality ratio derived from the APACHE II score was
0.69 (95% CI 0.68, 0.70) [28].
No causative organism was identified in over a third of
patients (Table 4). Streptococcus pneumoniae (Pneumococ-
cus) was the most commonly isolated organism (29% of
cases), Positive microbiology was obtained from lung secre-
tions/lavage in 47% of cases; blood culture in 22%; urinary
antigen testing in 17%; blood serology in 10%; pleural fluid
in 2.3% and other methods in 2%. Bacteraemia was present
in 241 (22%) of patients and pleural infection/empyema
in 32 (3%). Pneumococcus was the commonest organism
causing bacteraemia and empyema, accounting for 119
Table 2 Severity scoring, physiological variables and changes on chest radiographs
Clinical parameters Number analysed Median or number IQR or %
Scoring
APACHE II score 1,166 20 15 to 25
SOFA II score 1,158 6 4 to 9
IDSA/ATS criteria for severe CAP 1,161 1,140 97.8%
Physiology
Highest temperature, °C 1,160 38.0 37.2 to 38.6
Lowest temperature, °C 1,160 36.4 35.8 to 37
Lowest SBP, mmHg 1,161 91 80 to 105
Lowest MAP, mmHg 1,156 64 56 to 72
Highest heart rate. bpm 1,161 118 101 to 130
Lowest heart rate. bpm 1,161 84 70 to 95
Highest WCC, ×109/L 1,160 14.2 9.9 to 20.7
Lowest WCC, ×109/L 1,160 12.5 8.3 to 18
Lowest platelet count, ×109/L 1,160 197 142 to 266
Haematocrit, % 1089 34.7 30 to 39
Bicarbonate, mmol/L 1049 22 19 to 26
Lowest sodium, mmol/L 1,159 136 132 to 139
Lowest potassium, mEq/L 1,159 3.7 3.4 to 4.2
PCO2, mmHg 1,144 24 5.5 to 40
pH 1,150 7.33 7.24 to 7.42
Serum bilirubin, μmol/L 1,135 13 8 to 20
Urea, μmol/L 1,068 11 6.8 to 20
Urine volume, cL/day 1,153 155 90 to 236.5
Creatinine, μmol/L 1,161 100 72 to 157
Respiratory rate, bpm 1,154 27 18 to 35
P:F ratio, mmHg 1,150 132 86 to 200
Renal failure during week 1 in ICU 1,161 411 37.1
Need for RRT during week 1 in ICU 1,161 189 17.2
Mechanical ventilation during week 1 in ICU 1,161 962 85.0
Septic shock on admission 1,161 573 49.4
Admission CXR changes 1166
Lobar pattern on CXR 507 43.7
Localised pattern on CXR 290 25
Diffuse bilateral changes on CXR 340 29.3
All measurements recorded on day 1 of admission to the ICU unless stated otherwise. APACHE, acute physiology and chronic health evaluation; P:F ratio, ratio of
the partial pressure to fractional inspired concentration of oxygen; SOFA. sequential organ failure assessment; IDSA/ATS, Infectious Diseases Society of America/
American Thoracic Society; SBP, systolic blood pressure; MAP, mean arterial pressure; WCC, white cell count; CXR, chest radiograph.
Walden et al. Critical Care 2014, 18:R58 Page 4 of 9
http://ccforum.com/content/18/2/R58episodes (49%) and 25 episodes (60%) respectively. Atypical
organisms and viruses were rarely identified.
Univariate analysis
Isolation of Staphylococcus aureus, presence of septic
shock, need for mechanical ventilation and renal replace-
ment therapy all showed a strong association with out-
come (Table 5).Multivariate analysis
The factors most strongly associated with 28-day mor-
tality were the APACHE II score calculated on day 1
(HR = 1.03, CI 1.01, 1.05) for each 1.0-point increase in
score; haematocrit (HR = 0.97, CI 0.95, 0.99) for each 1%
absolute increase; pH (HR = 0.83, CI 0.72, 0.95) for each
0.1-point increase and the need for ventilator support
(HR = 2.29, CI 1.11, 4.72). Several other factors were
associated with 6-month outcome. APACHE II remained
Table 3 Mortality rates in a cohort of 1,166 patients with
community acquired pneumonia admitted to adult ICUs
across Europe
Time Mortality status Number %
6 months Alive 848 72.7
Dead 316 27.3
28 days Alive 964 82.7
Dead 202 17.3
Hospital Alive 881 75.6
Dead 285 24.4
ICU Alive 944 81.0
Dead 222 19.0
Table 4 Microbiological isolates from the GenOSept
cohort (n = 1,166)
Microbiology (organism) Number %
Streptococcus pneumoniae 333 28.6
Staphylococcus aureus 69 5.9
Legionella pneumophilia 65 5.5
Haemophilus influenzae 56 4.8
Pseudomonas aeroginosa 52 4.5
Klebsiella spp. 27 2.3
Chlamydia psittaci 10 0.9
Mycoplasma pneumoniae 10 0.9
Mixed 64 5.5
Viral 16 1.4
Other 144 12.4
Unknown 427 36.6
Other organisms included: Candida spp. 30 (2.6%), Escherichia coli 15 (1.3%),
Streptococcus spp.12 (1.0%), Enterobacter spp. 10 (0.9%), Serratia Marcesens
8 (0.7%).
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increase, as did haematocrit (HR = 0.97, CI 0.95, 0.98)
for each 1% increase. pH was strongly associated with
6-month outcome (HR = 0.86, CI 0.77, 0.96) for each 0.1
unit increase. Urine output on the first day was also asso-
ciated with 6-month outcome (HR = 0.98, CI 0.97, 0.99)
for each 100-mL increase in urine volume. Less strongly
associated with outcome were bilirubin (HR = 1.004,
CI 1.001, 1.006) and the lowest measured heart rate
(HR = 1.01, CI 1.00, 1.02) for each 1-beat increase. Of
the categorical variables, only diffuse bilateral changes
on chest radiography (HR = 1.44, CI 1.11, 1.78) and the
need for ventilator support (HR = 3.04, CI 1.64, 5.62) were
significantly associated with death (Table 6).
Discussion
This large, prospective study of 1,166 patients from 17 dif-
ferent countries provides a contemporary view of patientsDays
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Figure 1 Kaplan-Meier curve demonstrating survival probability
over a 6-month period for patients admitted to ICU with
community-acquired pneumonia (CAP).with severe CAP admitted to ICUs across Europe. The
mortality rates were 17% at 28 days, 19% at intensive
care discharge, 24% at hospital discharge and 27% at
6 months, giving a standardised mortality ratio based
on the APACHE II scores of 0.69 (95% CI 0.68, 0.70).
A number of studies have documented mortality rates
for patients with CAP admitted to ICU [5-7,9-22]. The
considerable heterogeneity in admission policies, study
design, guidelines compliance [21], and severity scoring
in these studies probably accounts for the wide range
of reported mortality rates and makes meaningful com-
parisons difficult. Most of these studies have used ICU
admission rather than severity scores to indicate severe
disease. Only three studies [12,18,21] defined censor points
for death, which is important as in-hospital mortality
increases following ICU discharge by between 15 and
27% [33]. Admission practices in different countries may
also lead to large ranges in mortality. Take for instance
one study of 395 patients admitted to a Spanish respira-
tory ICU in the 1990s the mortality rate was 5% but with
rates of mechanical ventilation and septic shock of 9%
and 2% respectively [14], whereas in a UK study published
in 1997 the mortality rate was 58%, with mechanical venti-
lation and septic shock rates of 96% and 16% respectively
[11]. The mortality rates reported here are more in keep-
ing with other recent, large cohorts. The CAPUCI group
analysed 529 patients admitted to over 30 Spanish ICUs
between 2000 and 2002 and found ICU mortality rates
of 28% with associated APACHE II scores of 19 [21]. They
included both immunocompetent and immunosuppressed
patients. In the 459 immunocompetent individuals the
rate of death at ICU discharge was slightly lower at
25%, a figure that is closer to the 19% seen in the GenOSept
cohort, (in which immunocompromised patients were
Table 5 Univariate Cox proportional hazards models for 28-day and 6-month mortality for patients admitted to the
ICU with CAP
Increment 28-day mortality 6-month mortality
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
APACHE II score 1.1 1.08, 1.12 <1E-14 1.08 1.07-1.1 0.00E + 00
Staphylococcus aureus 1.65 0.99, 2.75 5.59E-02 2.03 1.38, 2.97 3.02E-04
Haematocrit % 0.95 0.93, 0.98 2.98E-05 0.96 0.94, 0.98 6.19E-06
pH value 0.1 unit 0.7 0.62, 0.77 2.31E-11 0.75 0.69, 0.82 1.81E-10
Septic shock 1.98 1.48, 2.64 3.61E-06 1.6 1.28, 2 3.92E-05
Diffuse bilateral change on CXR 1.27 0.94, 1.7 1.14E-01 1.54 1.22, 1.94 2.44E-04
Bilirubin 10 μmol/L 1.04 1.02, 1.07 8.64E-04 1.04 1.02, 1.07 2.86E-04
Creatinine day 1 10 μmol/L 1.02 1.01, 1.03 1.41E-03 1.02 1.01, 1.03 1.85E-04
Lowest heart rate day 1 1.01 1, 1.02 2.35E-03 1.01 1.01, 1.02 4.62E-04
Lowest MAP day 1 0.97 0.96, 0.98 4.96E-06 0.98 0.97, 0.99 1.95E-06
Lowest SBP day 1 mmHg 0.98 0.97, 0.99 7.09E-08 0.98 0.98, 0.99 5.33E-07
Need for any ventilatory support 3.17 1.72, 5.82 2.01E-04 3.63 2.2, 6 5.07E-07
Mechanical ventilation 2.17 1.46, 3.21 1.19E-04 2.21 1.62, 3.03 6.41E-07
Renal failure in week 1 1.99 1.5, 2.64 2.04E-06 1.65 1.32, 2.07 1.40E-05
Need for renal replacement week 1 2.45 1.8, 3.32 9.00E-09 2.2 1.71, 2.82 6.09E-10
SOFAday1 1.12 1.08, 1.17 2.14E-08 1.11 1.08, 1.15 3.22E-10
Urine volume day 1 100 mL/day 0.97 0.96, 0.99 1.09E-04 0.97 0.96, 0.98 3.90E-06
All values are significant at a type I error rate of 5% after a Bonferroni correction to take account of the multiple testing of 64 variables (a P-value <0.00078 was
considered to be statistically significant). Results are adjusted for age and sex. All day-1 variables unless specified otherwise. RRT, renal replacement therapy; MV,
mechanical ventilation; NIV, non-invasive ventilation; SBP, systolic blood pressure; MAP, mean arterial pressure.
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of patients admitted to hospital with CAP of varying
severity, but have reported outcomes for the smaller
subgroup of patients admitted to the ICU. The GenIMS
investigators, for example examined a population of
1,895 CAP patients; 302 were admitted to the ICU, 52Table 6 Multivariate Cox proportional hazards model for
28-day and 6-month survival for patients admitted to the
ICU with CAP
Increment Hazard 95% CI P-value
28-day mortality
APACHE II score 1.06 1.03, 1.09 4.23E-05
Mechanical ventilation 2.29 1.11, 4.72 2.56E-02
Haematocrit 1% 0.97 0.95, 0.99 6.61E-03
pH value 0.1 unit 0.83 0.73, 0.95 7.52E-03
6-month mortality
APACHE II score 1.04 1.02, 1.06 5.67E-05
Mechanical ventilation 2.68 1.49, 4.85 1.06E-03
Urine volume day 1 100 mL/day 0.98 0.96, 0.99 1.28E-04
Lowest heart rate day 1 1.01 1.0, 1.01 4.60E-02
Haematocrit % 0.97 0.95, 0.99 4.78E-04
Diffuse bilateral CXR 1.38 1.07, 1.78 1.32E-02
Final model is selected using a stepwise regression by Akaike-information-criteria.
Results are adjusted for sex. Age correction included in APACHE II score. APACHE,
acute physiology and chronic health evaluation; CXR, chest radiography.(17.3%) of whom died during their hospital stay [3]. In the
PORT study, 170 of 1,339 patients were admitted to the
ICU with an in-hospital mortality rate of 23.3% [24].
The standard censor point for most interventional ICU
studies is 28 days, although it is recognised that there is
a significant attrition rate post ICU discharge. It is also
well-recognised that in CAP patients there is an increased
death rate in the months following discharge [34], and in
patients with sepsis there is significant excess mortality for
at least five years [35]. In one study, the death rate of ICU
patients between 28 days and 6 months was 9% in patients
with sepsis, similar to the 8% seen in ICU patients without
sepsis [36] and the 10% found in the present study. This
compares to an increase in mortality from 18.2% at 30 days
to 24.8% at 90 days in the subgroup of ICU patients in the
PORT study [24] and an increase from 17.3% to 34.8% at
12 months in the GenIMS cohort of ICU patients [3].
Although the microbiological methodology was not
standardised, our findings are consistent with previous
studies of severe CAP. Notably, Streptococcus pneumoniae
accounted for 28% of all cases and no aetiological agent
was identified in over a third [37]. Within the GenOSept
cohort the rate of Streptococcus pneumoniae was higher
than previously reported and was mirrored by a decrease
in the number of cases where no aetiological agent was
identified, suggesting that detection rates may have
improved, rather than there being a true increase in
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bodily fluids has become the standard of care in many
institutions and has good positive and negative predictive
value both in hospitalised CAP patients [38] and in those
admitted to ICU [39]. Amongst the 333 patients with
confirmed pneumococcal pneumonia in the present
study, a total of 429 positive results were obtained. Of
these 123 (29%) were positive urinary antigen tests and 42
(10%) were based on positive blood serology. Further
evidence to support this apparent increase in detection
rates is provided by a recent study that reported detection
rates of 50% for Streptococcus pneumoniae, with 16% of
cases being diagnosed using antigen testing [21]. In com-
parison, the BTS study from 1992 reported a rate of
Streptococcus pneumoniae infection of 18%, with positive
antigen testing in only 6% of patients [7,21].
In hospitalised patients with CAP, as many as 18 to
29% may involve a viral infection, the virus being the
only organism isolated in 10% [40]. Failure to respond to
standard antimicrobial therapy means that more patients
with viral pneumonia are likely to be admitted to ICU.
Certainly patients with co-morbidities have a higher inci-
dence of viral infection. In the present study viral infections
were rarely identified. This raises the question as to
whether a more aggressive search for viral pathogens
should be conducted in all ventilated patients, coupled
with more frequent and targeted use of antiviral therapy.
Multivariate analysis identified four variables (APACHE
II score, haematocrit, mechanical ventilation and pH) that
were independently associated with outcome at both
28 days and 6 months The need for mechanical ventilation
was related to a worse outcome at both 28 days and
6 months, consistent with other data showing respira-
tory failure to be an independent predictor of mortality
in many categories of critically ill patients [28,29]. The
persistence of this relationship for up to 6 months reflects
the fact that many patients who have received ventilator
support will continue to have significant neuromuscular
weakness and be at risk for a prolonged period after dis-
charge from the ICU [41]. It may be that over-aggressive
use of intravenous fluids, reflected in a dilutional reduction
in haematocrit worsens lung injury and thus prolongs
the need for mechanical ventilation. Conservative fluid
management has been associated with better outcomes,
albeit in the later phases of critical illness [42]. A key
element of early goal-directed therapy in patients with
sepsis is blood transfusion to maintain the haematocrit,
perhaps accounting for the positive association between
better outcomes and a higher haematocrit in the present,
and other studies [43]. Similarly the positive independent
relationship between a higher pH on admission and a better
outcome may reflect more effective early resuscitation.
Although there was no association between the admis-
sion P:F ratio and outcome, diffuse bilateral changes onthe chest radiograph (suggesting a diagnosis of acute lung
injury/acute respiratory distress syndrome) independently
predicted a worse outcome at 6 months. This is consistent
with other studies showing a mortality rate for ARDS
much higher than that seen in our cohort of patients with
CAP [41].
Urine volume, renal failure and the need for renal re-
placement therapy were associated with worse outcome in
the univariate analysis and there was a clear independent
association between urine output and mortality at 6 months.
Acute kidney injury (AKI) has been shown to be independ-
ently associated with higher ICU and in hospital mortality
rates [44,45]. The need for ongoing renal support in those
with AKI is estimated to be 14%, perhaps explaining the
association with outcome at 6 months.
Other studies have attempted to determine independent
risk factors for death from CAP. For example, the presence
of septic shock has been associated with odds ratios for risk
of death ranging from 2 to 141 but inevitably with wide
confidence intervals due to the small numbers of patients
included in these analyses [5,6,15,16,22]; also the lack of a
consistent censor point complicates interpretation of these
findings. We found an association between septic shock
and outcome on univariate analysis but this effect was not
seen in multivariate analysis, perhaps reflecting improve-
ments in the acute management of shock.
This study has two important limitations. Firstly partici-
pating centres were at liberty to decide which patients
they would enrol; subjects were not, therefore, enrolled
consecutively, thereby introducing a potential for selection
bias. Also there was considerable variation in the number
of patients recruited in each country and some centres
contributed only small numbers of patients. Nevertheless
there was a wide range of ages, severity of physiological
derangement and co-morbidities, whereas APACHE II
scores and ventilation rates were similar to previous
studies, suggesting that a significant, systematic selection
bias is unlikely. Secondly, microbiological protocols were
not standardised. On the other hand our observations
therefore reflect current approaches to microbiological
diagnosis in routine clinical practice across Europe.
Conclusion
The ICU mortality rate in this contemporary cohort of
patients admitted to ICUs across Europe with severe
CAP was 19%, rising to 24% at hospital discharge and 27%
at 6 months. Streptococcus pneumoniae was the common-
est cause of CAP, but in many cases the infecting organism
was not identified. The need for ventilator support, and
the presence of diffuse bilateral infiltrates on the chest
radiograph, as well as lower haematocrit, urine volume
and pH on admission to ICU were independent predictors
of a worse outcome.
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 The mortality rate from severe CAP in patients
admitted to ICU is 27% at six months
 Streptococcus pneumonia remains the most
commonly isolated organism
 No microbiological diagnosis is found in a third
of patients
 The need for mechanical ventilation is a strong
predictor of a poor outcome
 pH, haematocrit, urine output and diffuse changes
on chest radiography all predict a worse outcomeAdditional file
Additional file 1: List of variables included in univariate analysis.
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